Impact of steatosis on perioperative outcome following hepatic resection.

PubWeight™: 2.05‹?› | Rank: Top 2%

🔗 View Article (PMID 14675713)

Published in J Gastrointest Surg on December 01, 2003

Authors

David A Kooby1, Yuman Fong, Arief Suriawinata, Mithat Gonen, Peter J Allen, David S Klimstra, Ronald P DeMatteo, Michael D'Angelica, Leslie H Blumgart, William R Jarnagin

Author Affiliations

1: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

Articles citing this

Guidelines for resection of colorectal cancer liver metastases. Gut (2006) 2.35

Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). HPB (Oxford) (2011) 1.56

Steatosis as a risk factor in liver surgery. Ann Surg (2007) 1.48

Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg (2007) 1.42

A prospective, randomized, controlled trial comparing intermittent portal triad clamping versus ischemic preconditioning with continuous clamping for major liver resection. Ann Surg (2006) 1.39

Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer (2007) 1.16

Severe steatosis increases hepatocellular injury and impairs liver regeneration in a rat model of partial hepatectomy. Ann Surg (2007) 1.09

2012 Liver resections in the 21st century: we are far from zero mortality. HPB (Oxford) (2013) 1.07

The effects of cancer chemotherapy on liver imaging. Eur Radiol (2009) 1.04

Treatment of colorectal liver metastases. World J Surg Oncol (2011) 1.04

The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study. Virchows Arch (2007) 1.04

New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res (2007) 1.03

Future remnant liver function estimated by combining liver volumetry on magnetic resonance imaging with total liver function on (99m)Tc-mebrofenin hepatobiliary scintigraphy: can this tool predict post-hepatectomy liver failure? HPB (Oxford) (2016) 1.00

Body mass index and adverse perioperative outcomes following hepatic resection. J Gastrointest Surg (2010) 0.98

Evolution of laparoscopic left lateral sectionectomy without the Pringle maneuver: through resection of benign and malignant tumors to living liver donation. Surg Endosc (2010) 0.97

Safety of liver resections in obese and overweight patients. World J Surg (2010) 0.96

Hepatic ischemia-reperfusion injury: roles of Ca2+ and other intracellular mediators of impaired bile flow and hepatocyte damage. Dig Dis Sci (2006) 0.95

Colorectal liver metastases. Int J Surg Oncol (2011) 0.93

Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol (2013) 0.93

Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation. J Am Coll Surg (2010) 0.90

Contrast-enhanced computed tomography for the diagnosis of fatty liver: prospective study with same-day biopsy used as the reference standard. Eur Radiol (2009) 0.90

Perfusion CT findings in liver of patients with tumor during chemotherapy. World J Gastroenterol (2010) 0.90

Thermal tumor ablation therapy for colorectal cancer hepatic metastasis. J Gastrointest Oncol (2012) 0.87

Metastatic colorectal cancer outcome and fatty liver disease. Nat Rev Gastroenterol Hepatol (2013) 0.87

Laparoscopic liver resection in obese patients. World J Surg (2015) 0.87

Liver resection in obese patients: results of a case-control study. HPB (Oxford) (2010) 0.87

Contrast-enhanced 3D ultrasound in the radiofrequency ablation of liver tumors. World J Gastroenterol (2009) 0.86

Effect of metabolic syndrome on perioperative outcomes after liver surgery: A National Surgical Quality Improvement Program (NSQIP) analysis. Surgery (2012) 0.86

Perioperative management of hepatic resection. J Gastrointest Oncol (2012) 0.86

Hypertrophy of the non-embolized liver after chemotherapy. HPB (Oxford) (2009) 0.86

A comparison of right posterior sectorectomy with formal right hepatectomy: a dual-institution study. HPB (Oxford) (2013) 0.85

A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer (2009) 0.85

National trends in discharge disposition after hepatic resection for malignancy. HPB (Oxford) (2011) 0.85

The association between preoperative chemotherapy and the prevalence of hepatic steatosis in hepatectomy for metastatic colorectal cancer. Arq Bras Cir Dig (2014) 0.84

Influence of preoperative chemotherapy on the intraoperative and postoperative course of liver resection for colorectal cancer metastases. World J Surg (2012) 0.83

Patient selection for hepatic resection for metastatic colorectal cancer. J Gastrointest Oncol (2012) 0.82

Role of quantification of hepatic steatosis and future remnant volume in predicting hepatic dysfunction and complications after liver resection for colorectal metastases: a pilot study. HPB (Oxford) (2012) 0.82

mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury. HPB (Oxford) (2011) 0.82

Multi-modality treatment of colorectal liver metastases. World J Gastroenterol (2012) 0.82

The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy. HPB (Oxford) (2012) 0.81

Surgical treatment of hepatic metastases from colorectal cancer. World J Gastrointest Oncol (2011) 0.80

Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review. Int J Clin Oncol (2011) 0.79

Intraabdominal bacterial infections significantly alter regeneration and function of the liver in a rat model of major hepatectomy. Langenbecks Arch Surg (2007) 0.79

Prospective multicenter phase II clinical trial of FOLFIRI chemotherapy as a neoadjuvant treatment for colorectal cancer with multiple liver metastases. J Korean Surg Soc (2013) 0.79

A comprehensive method for predicting fatal liver failure of patients with liver cancer resection. Medicine (Baltimore) (2015) 0.79

Strategies for Management of Synchronous Colorectal Metastases. Curr Surg Rep (2014) 0.79

Feasibility and potential benefit of preoperative chemotherapy for colorectal liver metastasis (CLM): a single-centered retrospective study. Surg Today (2012) 0.78

Metabolic syndrome and hepatic resection: improving outcome. HPB (Oxford) (2011) 0.78

Drug-induced steatohepatitis. Clin Liver Dis (2013) 0.78

Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases. Int J Colorectal Dis (2011) 0.78

Role of surgery in colorectal liver metastases: too early or too late? World J Gastroenterol (2010) 0.78

Hydrolyzed whey peptide-based diet ameliorates hepatic ischemia-reperfusion injury in the rat nonalcoholic fatty liver. Surg Today (2014) 0.78

Hepatic steatosis prevents heme oxygenase-1 induction by isoflurane in the rat liver. World J Gastroenterol (2011) 0.77

Surgical options for initially unresectable colorectal liver metastases. HPB Surg (2012) 0.77

Hepatocyte apoptosis is enhanced after ischemia/reperfusion in the steatotic liver. J Clin Biochem Nutr (2011) 0.77

An accurate predictor of liver failure and death after hepatectomy: a single institution's experience with 478 consecutive cases. World J Gastroenterol (2014) 0.77

Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer. World J Gastroenterol (2009) 0.77

Advances in therapeutics for liver metastasis from colorectal cancer. World J Gastrointest Oncol (2010) 0.77

The Interaction between Diabetes, Body Mass Index, Hepatic Steatosis, and Risk of Liver Resection: Insulin Dependent Diabetes Is the Greatest Risk for Major Complications. HPB Surg (2014) 0.77

A case of liver fibrosis with splenomegaly after oxaliplatin-based adjuvant chemotherapy for colon cancer. J Korean Med Sci (2013) 0.77

A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics. Int J Hepatol (2013) 0.76

Successful combination therapy of radical liver resection with 5-fluorouracil/leucovorin, oxaliplatin, plus bevacizumab for ascending colon cancer with pulmonary and 43 liver metastases: report of a case. Int Surg (2012) 0.76

Liver surgery in the presence of cirrhosis or steatosis: Is morbidity increased? Patient Saf Surg (2008) 0.76

Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases. World J Gastroenterol (2006) 0.75

Acute renal injury after partial hepatectomy. World J Hepatol (2016) 0.75

The role of peri-operative treatment in resectable liver metastases of colorectal cancer. Ther Adv Med Oncol (2010) 0.75

Portal vein embolization for induction of selective hepatic hypertrophy prior to major hepatectomy: rationale, techniques, outcomes and future directions. Cancer Biol Med (2016) 0.75

Chemotherapy and its effect on liver hypertrophy: implications for portal vein embolization and resection. Semin Intervent Radiol (2008) 0.75

Steatosis as a risk factor in liver surgery. Ann Surg (2007) 0.75

Influence of Kupffer cells and platelets on ischemia-reperfusion injury in mild steatotic liver. World J Gastroenterol (2013) 0.75

Ischemic preconditioning attenuates ischemia/reperfusion injury in rat steatotic liver: role of heme oxygenase-1-mediated autophagy. Oncotarget (2016) 0.75

The influence of steatosis on the short- and long-term results of resection of liver metastases from colorectal carcinoma. HPB (Oxford) (2016) 0.75

Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1 H MRS study. NMR Biomed (2012) 0.75

Administration of multipotent mesenchymal stromal cells restores liver regeneration and improves liver function in obese mice with hepatic steatosis after partial hepatectomy. Stem Cell Res Ther (2017) 0.75

Hepatic histopathology and postoperative outcome after preoperative chemotherapy for Chinese patients with colorectal liver metastases. World J Gastrointest Surg (2013) 0.75

Good candidates for a third liver resection of colorectal metastasis. World J Surg (2013) 0.75

Blood transfusions and steatohepatitis are independent risk factors for complications following liver resection for colorectal cancer liver metastases. Mol Clin Oncol (2017) 0.75

Risk factors for acute kidney injury after partial hepatectomy. World J Hepatol (2017) 0.75

Articles by these authors

Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26

Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36

Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg (2002) 8.30

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 7.99

CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest (2008) 5.96

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res (2005) 5.44

The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20

Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03

Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95

Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature (2008) 4.87

Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83

An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74

Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol (2002) 4.16

Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol (2005) 3.99

Solid-pseudopapillary tumor of the pancreas: a surgical enigma? Ann Surg Oncol (2002) 3.96

Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol (2007) 3.85

Pasireotide for postoperative pancreatic fistula. N Engl J Med (2014) 3.84

MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J Exp Med (2007) 3.79

Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51

NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40

Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell (2012) 3.39

A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg (2006) 3.34

Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet (2012) 3.33

Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol (2003) 3.27

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20

Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20

Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16

Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16

Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg (2003) 3.14

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12

Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol (2004) 3.08

NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas (2010) 3.00

Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg (2010) 2.99

Electronic synoptic operative reporting: assessing the reliability and completeness of synoptic reports for pancreatic resection. J Am Coll Surg (2010) 2.98

Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer (2003) 2.96

Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg (2004) 2.86

Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst (2010) 2.79

Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid (2010) 2.77

Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76

Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol (2012) 2.74

Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res (2005) 2.73

Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.66

Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak (2008) 2.64

Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med (2003) 2.62

The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer (2004) 2.54

American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol (2009) 2.52

Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51

Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Ther (2006) 2.45

The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas (2010) 2.43

Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol (2011) 2.42

Gastrointestinal stromal tumor: 5 years later. Cancer (2005) 2.40

Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol (2002) 2.39

Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg (2005) 2.38

Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol (2012) 2.38

Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg (2007) 2.37

Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg (2003) 2.36

Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol (2003) 2.36